Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Z-MARK: Zoledronic Acid Dosing in Multiple Myeloma
NCT00622505Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2007
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in multiple myeloma (MM), sponsored by Novartis. Primary endpoint: Percentage of Participants With ≥1 Skeletal Related Event (SRE) at the End of 1 Year on Study. Started Nov 2007; status: completed.
02
Drugs
zoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00622505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622505.